Drug Approval | April 27, 2023
Ipca Laboratories gets 3 observations for Piparia, Silvassa unit
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company will set up a MRI, CT Scan, Sonography- Ultrasound, X-Ray Center and Pathology Lab
Monika and Prathmesh’s determination to participate in the Dream Run to increase awareness serves as a testament to life changing effects of organ transplants and importance of organ donation
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Selexipag tablet is indicated in adults for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization for PAH
40,000 visitors and representatives of more than 80 countries set to visit the show
The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Subscribe To Our Newsletter & Stay Updated
